At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 10, 2026 at 07:00 ET
Gain Therapeutics reported Q3 2026 net loss of $0.07 per share, narrower than the $0.15 loss a year ago and better than the $-0.13 consensus. Cash burn continues with $11.7M on hand, and the company expects to start a Phase 2 trial of rexaceract in Q1 2027.
- Net loss per share $0.07 for Q3 2026 vs $0.15 in Q3 2025
- Cash and cash equivalents $11.7M as of Sep 30, 2026, down from $20.8M at Dec 31, 2025
- Phase 2 trial of rexaceract expected to begin in Q1 2027
- R&D expenses fell to $1.4M from $2.8M year-over-year
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access